CELL INTELLIGENCE · 肿瘤细胞治疗研究

成人 B 细胞急性淋巴细胞白血病患者的高危特征：在靶向免疫治疗时代重新定义风险

High-risk features in adult patients with B-cell acute lymphoblastic leukemia: redefining risk in the era of targeted immunotherapy.

B 细胞淋巴瘤中 T 细胞导向免疫治疗失败后接受异基因造血干细胞移植：真实世界病例系列及系统性文献综述

Allogeneic hematopoietic stem cell transplantation following T-cell-directed immunotherapy failure in B-cell lymphoma: a real-world case series and sy

套细胞淋巴瘤的个体化策略：以专家小组意见优化治疗范式

Tailored approaches in mantle cell lymphoma: refining treatment paradigms with an expert panel opinion.

用于 CD19 CAR-T 疗效、药代动力学与安全性整合评价的 B 细胞急性淋巴细胞白血病异种移植大鼠模型验证

Validation of a B cell acute lymphoblastic leukemia xenograft rat model for integrated efficacy, pharmacokinetics and safety of CD19 CAR-T.

基于抗 CD19（FMC63）Traptavidin 融合蛋白的四聚体生物素-亲和素支架构建用于白血病治疗的高亲合力 CAR-T 细胞

A Tetrameric Biotin-Avidin Scaffold Using Anti-CD19 (FMC63) Traptavidin Fusion Enables High-Avidity CAR-T Cells for Leukemia Therapy.

tisagenlecleucel 治疗复发/难治性 B 细胞恶性肿瘤的预后因素与结局：一项单中心真实世界研究

Prognostic factors and outcomes of tisagenlecleucel in relapsed or refractory B-cell malignancies: a single-center real-world study.

Tisa-cel 治疗在韩国 R/R B 细胞恶性肿瘤患者中可行且有效。单核细胞负荷和采集产物中 CD3+ T 细胞质量等治疗前免疫参数显著影响 DLBCL 的结局。这些发现提示，优化患者选择和改进生产策略可能增强 CAR-T 疗效，尤其是在资源受限或异质性较大的真实世界环境中。

肿瘤预激 CD8⁺ 自然杀伤 T 样细胞作为复发/难治性多发性骨髓瘤的高效新型细胞疗法

Tumor-priming CD8(+) natural killer T-like cells as an efficient novel cell therapy for relapsed/refractory multiple myeloma.

TPNC 是一种通过肿瘤驱动的致敏产生的新型细胞毒性淋巴细胞产品。

白血病异种移植小鼠中的 CD19 CAR-T 细胞治疗：抗白血病疗效、动力学与 4 周单次给药毒性

CD19 chimeric antigen receptor T cell therapy in leukemia xenograft mouse: Anti-leukemic efficacy, kinetics, and 4-week single-dose toxicity.

浆细胞样树突状细胞肿瘤

Plasmacytoid dendritic cell neoplasms.

CD19/CD22 双特异性嵌合抗原受体 NK-92 细胞的开发与评价

CD19/CD22 bispecific chimeric antigen receptor‑NK‑92 cells are developed and evaluated.